Trust Signals
- Written by the FormBlends Medical Team, which includes licensed clinicians and medical writers with backgrounds in endocrinology and pharmacology.
- All clinical claims are graded by evidence type. Speculative statements are labeled as such.
- No affiliate links to specific product brands. No sponsored claims.
- Sources are limited to FDA labeling, peer-reviewed trials, and PubMed-indexed pharmacokinetic studies.
- Last reviewed: May 29, 2026.
Key Takeaways
- The FDA-approved weight-loss maintenance dose is 3 mg daily, reached over a four-step titration spanning four weeks.
- The SCALE Obesity and Prediabetes trial (n = 3,731) showed a mean 8.4% body weight reduction at 3 mg versus roughly 2.8% for placebo over 56 weeks.
- Liraglutide's half-life is approximately 13 hours, making once-daily dosing the correct pharmacological interval.
- The Victoza maximum dose of 1.8 mg is approved only for type 2 diabetes, not weight loss, and produces less weight reduction than 3 mg in available data.
- If three or more consecutive doses are missed, clinical guidance recommends restarting titration from 0.6 mg to prevent severe GI adverse effects on return to full dose.
What Is the Right Liraglutide Dosage for Weight Loss?
The correct liraglutide dosage for weight loss is 3 mg subcutaneously once daily (Saxenda), reached by increasing 0.6 mg every week over four weeks. This dose is FDA-approved for chronic weight management in adults with BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity. The Victoza 1.8 mg diabetes dose is not an approved weight-loss regimen.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Standard titration schedule and Victoza dosing chart
- How liraglutide produces weight loss: mechanism with numbers
- Evidence ledger: what the trials actually showed
- What happens if you miss a dose or stop and restart?
- What most dosage pages get wrong
- Storage and stability: the chemistry behind the rules
- Honest head-to-head: liraglutide vs semaglutide vs phentermine-topiramate
- Label and COA literacy: how to read your pen or vial
- Who should not use liraglutide at any dose?
- FAQ
What Is the Standard Titration Schedule and Victoza Dosing Chart?
| Week | Saxenda Dose (Weight Loss) | Victoza Dose (Diabetes) | Purpose of Step |
|---|---|---|---|
| 1 | 0.6 mg daily | 0.6 mg daily | GI habituation; not a therapeutic weight-loss dose |
| 2 | 1.2 mg daily | 1.2 mg daily (often maintained) | Initial glycemic/appetite effect |
| 3 | 1.8 mg daily | 1.8 mg daily (max for T2D) | Submaximal weight-loss dose |
| 4 | 2.4 mg daily | Not approved above 1.8 mg | Continued GI adaptation |
| 5 onward | 3.0 mg daily | Not approved above 1.8 mg | FDA-approved weight-loss maintenance dose |
Patients who cannot tolerate a dose increase may extend any step by an additional week. The prescribing information for Saxenda (Novo Nordisk, FDA label revised 2023) states that if the 3 mg dose is not tolerated, the drug should be discontinued rather than maintained at a lower dose long-term for weight loss, because sub-maximal doses have not demonstrated adequate weight-loss efficacy in that indication.
How Does Liraglutide Produce Weight Loss: Mechanism With Numbers
Liraglutide is a GLP-1 receptor agonist with 97% amino acid sequence homology to native human glucagon-like peptide-1. It is a longer peptide analogue of GLP-1 modified with a C18 fatty diacid side chain that binds albumin in plasma, extending its half-life to approximately 13 hours after subcutaneous injection, compared to the roughly 2-minute half-life of endogenous GLP-1.
Relevant receptor-level effects for weight loss:
- GLP-1 receptors in the hypothalamic arcuate nucleus signal satiety and reduce food intake. Animal studies show dose-dependent reduction in meal size; human data confirm reduced caloric intake relative to placebo in controlled feeding studies, though the magnitude varies by study design.
- Gastric emptying is slowed, prolonging post-meal fullness. This effect is most pronounced at lower doses and partially attenuates at steady state, which is one reason the weight-loss effect requires 3 mg rather than 1.2 mg.
- Hepatic glucose production is suppressed, contributing to glycemic benefit but not directly to fat loss per se.
Evidence Ledger: What Do the Trials Actually Show?
| Claim | Best Evidence | Key Data | Confidence |
|---|---|---|---|
| 3 mg liraglutide produces meaningful weight loss vs placebo | Human RCT (SCALE Obesity and Prediabetes; Pi-Sunyer et al., NEJM 2015, n=3,731) | Mean 8.4% body weight loss at 56 weeks vs 2.8% placebo | High |
| Titration reduces GI side effects | FDA labeling, mechanistic rationale, sub-group analyses | Nausea most common adverse event, peaks early in titration then declines | Moderate |
| 3 mg is superior to 1.8 mg for weight loss | Dose-finding RCT (Astrup et al., Lancet 2009, n=564) | Dose-dependent weight loss across 1.2, 1.8, 2.4, 3.0 mg arms; 3 mg produced greatest loss | High |
| Weight regain occurs after stopping | Human RCT follow-up (SCALE extension data) | Participants regained most lost weight within 12 weeks of stopping | High |
| Cardiovascular safety at weight-loss doses | Human RCT (LEADER trial used 1.8 mg in T2D, not 3 mg weight-loss dose) | LEADER showed CV benefit at 1.8 mg in T2D; extrapolation to 3 mg weight-loss population is indirect | Moderate |
| Thyroid C-cell risk in humans | Animal data (rodent studies), case surveillance; no confirmed human RCT signal | Black box warning based on rodent tumors; human relevance unclear | Low (for humans) |
What Happens if You Miss a Dose or Stop and Restart?
Liraglutide's approximately 13-hour half-life means a single missed day results in noticeably lower plasma levels, but no acute harm. The practical rules are:
- Missed dose, same day: take as soon as remembered.
- Missed dose, more than 12 hours elapsed: skip and resume the next scheduled day. Do not double dose.
- Three or more consecutive days missed: the Saxenda prescribing information recommends restarting titration from 0.6 mg. This is because GI tolerance, not pharmacokinetics alone, resets with a gap. Returning directly to 3 mg after several days off carries a high nausea and vomiting burden.
What Most Dosage Pages Get Wrong
Most competitor dosage guides make at least one of these errors:
- Conflating Victoza and Saxenda doses. Victoza tops out at 1.8 mg and is approved only for type 2 diabetes and cardiovascular risk reduction, not weight loss. Using a Victoza dosing chart to guide weight-loss titration undershoots the therapeutic target by a full step.
- Ignoring the missed-dose restart protocol. Standard articles list injection instructions but omit what to do after a supply gap. This is one of the most common real-world adherence failure points.
- Presenting weight loss percentages without trial context. The 8.4% mean weight loss in SCALE was in participants who also received lifestyle intervention. Weight loss with liraglutide alone, without counseling, is likely lower. The trial context changes the realistic expectation.
- Claiming liraglutide is equivalent to semaglutide. It is not. Head-to-head and trial comparisons consistently show semaglutide produces greater weight loss. See the comparison table below.
- Omitting the discontinuation rate. In SCALE, roughly 10% of participants in the liraglutide arm discontinued due to adverse events, mostly GI. This is not a rare outcome; it shapes realistic counseling.
Storage and Stability: The Chemistry Behind the Rules
Liraglutide is a peptide analogue of GLP-1 with a C18 fatty diacid modification, dissolved in an aqueous formulation at pH 8.15, with phenol as a preservative and propylene glycol as a stabilizer.
Why refrigerate before opening? Peptide bonds and the amide linkages in the liraglutide backbone undergo hydrolysis faster at higher temperatures. The rate of hydrolysis is exponential with temperature (Arrhenius relationship). Refrigeration (2 to 8 degrees Celsius) keeps this degradation negligible during the labeled shelf life.
Why is 30 days the in-use limit at room temperature? Novo Nordisk's stability studies (summarized in FDA labeling) established that physical and chemical integrity is maintained for up to 30 days at up to 25 degrees Celsius once the pen is in use. Beyond that window, aggregation and deamidation accumulate to the point where potency cannot be guaranteed.
Why never freeze? Ice crystal formation damages the peptide's three-dimensional structure and disrupts the micellar/albumin-binding conformation conferred by the fatty acid chain. A frozen-then-thawed pen may look identical but deliver degraded or aggregated peptide. There is no reliable visual test for freeze damage, which is why the rule is absolute: if a pen has frozen, discard it.
Light exposure: The pen cap should remain on when not in use. UV photodegradation of aromatic amino acid residues (tryptophan, tyrosine, phenylalanine) is a real but slower degradation pathway. The opaque pen casing provides adequate protection under normal use; do not store pens on a windowsill or dashboard.
Honest Head-to-Head: Liraglutide vs Semaglutide vs Phentermine-Topiramate
| Factor | Liraglutide 3 mg (Saxenda) | Semaglutide 2.4 mg (Wegovy) | Phentermine-Topiramate ER (Qsymia) |
|---|---|---|---|
| Mean weight loss (pivotal trial) | ~8.4% (SCALE, 56 wks) | ~15% (STEP 1, 68 wks) | ~10% at top dose (CONQUER, 56 wks) |
| Injection frequency | Daily | Weekly | Oral, daily |
| CV outcome trial | Indirect (LEADER at 1.8 mg in T2D) | SELECT trial showed CV benefit | No dedicated CV outcomes trial |
| Main side effect | Nausea, vomiting (GI) | Nausea, vomiting (GI) | Paresthesia, cognitive effects, teratogenicity |
| Contraindication: MEN2/MTC | Yes (black box) | Yes (black box) | No |
| Pregnancy | Contraindicated | Contraindicated | Contraindicated (category X) |
| Where liraglutide loses | Lower weight loss than semaglutide; daily injection burden | Wins on weight loss and dosing frequency | Oral route advantage; lower cost in some markets |
| Where liraglutide wins | Longer real-world safety record than semaglutide; more prescriber familiarity | GLP-1 mechanism may have broader metabolic benefits |
The honest conclusion: for most patients requiring pharmacologic weight management, semaglutide 2.4 mg produces greater weight loss with fewer injections. Liraglutide remains a reasonable choice when semaglutide is unavailable, contraindicated, or not tolerated, and when a prescriber has strong familiarity with Saxenda titration.
Label and COA Literacy: How to Read Your Pen or Verify a Compounded Vial
FDA-approved pens (Saxenda, Victoza):
- Saxenda pens deliver 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg per injection. Each pen contains 18 mg/3 mL (6 mg/mL concentration). Confirm the concentration on the label matches 6 mg/mL before the first use.
- The needle is not included; it must be purchased separately (NovoFine or compatible 4 to 8 mm 32G needles are standard). A pen dispensing without a needle attached does nothing.
- Check the liquid: it should be clear and colorless to almost colorless. Do not use a pen with particulate matter, cloudiness, or unusual color.
Compounded liraglutide vials (where legally dispensed):
- Request a Certificate of Analysis (COA) from an accredited third-party lab (USP-compliant). The COA should show: peptide purity (typically 95% or higher by HPLC), endotoxin levels (USP limits for injectable compounds), sterility testing result, and concentration verification.
- Reconstitution is not required for liraglutide (it is supplied in solution), but concentration may vary from compounders. If the vial states a concentration other than 6 mg/mL, all doses must be recalculated. Dose by mass (milligrams), not by volume alone.
- A degraded or subpotent compounded peptide will not produce expected efficacy but may not look different. COA verification is not optional if you are using a compounded product.
Who Should Not Use Liraglutide at Any Dose?
- Personal or family history of medullary thyroid carcinoma (MTC). The black box warning is based on rodent C-cell tumor data; human relevance has not been confirmed but the risk cannot be excluded.
- Multiple endocrine neoplasia syndrome type 2 (MEN2), which predisposes to MTC.
- Known hypersensitivity to liraglutide or any product excipient (phenol, propylene glycol, sodium phosphate dibasic dihydrate).
- Pregnancy. GLP-1 receptor agonists are not recommended; animal studies show harm at relevant doses.
- Serious active gallbladder disease (relative contraindication; GLP-1 agonists reduce gallbladder motility and have been associated with gallstone formation in longer-term use).
- History of pancreatitis warrants caution; causality between GLP-1 agonists and pancreatitis has not been definitively established in RCTs, but FDA labeling includes a precaution and recommends discontinuation if pancreatitis is confirmed.
FAQ
What is the correct liraglutide dosage for weight loss?
The FDA-approved weight-loss dose is 3 mg daily (Saxenda), reached by titrating 0.6 mg per week over four weeks. The diabetes dose (Victoza, max 1.8 mg) produces less weight loss in head-to-head data.
How long does the liraglutide titration schedule take?
The standard titration takes four weeks to reach the 3 mg maintenance dose: 0.6 mg for week 1, 1.2 mg for week 2, 1.8 mg for week 3, 2.4 mg for week 4, then 3 mg from week 5 onward.
Can the Victoza 1.8 mg dose be used for weight loss?
Victoza is not FDA-approved for weight loss. The SCALE Obesity and Prediabetes trial showed the 3 mg dose produced roughly 8.4% mean body weight loss versus a lower effect at 1.8 mg, which is not an approved weight-loss dose.
What happens if you skip a titration step?
Jumping dose steps increases nausea, vomiting, and the likelihood of discontinuing therapy. GLP-1 receptors in the gut need gradual exposure. Slowing titration is always safer than accelerating it.
How is liraglutide injected and where?
Subcutaneous injection into the abdomen, thigh, or upper arm. Rotate sites. Time of day does not matter clinically, but consistency aids habit formation. Do not inject into a vein or muscle.
What should a patient do if they miss a liraglutide dose?
Take the missed dose the same day if remembered. If more than 12 hours have passed, skip it and resume the next day. Never double dose. If three or more days are missed, restart titration from 0.6 mg to avoid GI side effects.
How does liraglutide compare to semaglutide for weight loss?
Semaglutide 2.4 mg weekly (Wegovy) produces roughly 15% mean body weight loss versus roughly 8.4% for liraglutide 3 mg daily in their respective pivotal trials. Semaglutide requires one injection per week versus daily for liraglutide.
Is liraglutide dosage different for people with type 2 diabetes?
Yes. In type 2 diabetes, Victoza is dosed at 0.6 mg for one week, then 1.2 mg, with a maximum of 1.8 mg for glycemic control. The weight-loss indication requires the higher 3 mg Saxenda protocol.
Does liraglutide need to be refrigerated?
Unopened pens must be stored at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). Once in use, the pen can be kept at room temperature (up to 77 degrees Fahrenheit, 25 degrees Celsius) or refrigerated for up to 30 days. Never freeze liraglutide.
Who should not use liraglutide?
Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, and known hypersensitivity to liraglutide or any excipient.
What is the half-life of liraglutide and why does it matter for dosing?
Liraglutide has a half-life of approximately 13 hours after subcutaneous injection, which is what makes once-daily dosing pharmacologically appropriate. Semaglutide's roughly 7-day half-life allows weekly dosing.
Sources
- Pi-Sunyer X, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management." New England Journal of Medicine. 2015;373(1):11-22. (SCALE Obesity and Prediabetes trial, n=3,731)
- Astrup A, et al. "Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study." Lancet. 2009;374(9701):1606-1616. (Dose-finding trial, n=564)
- Marso SP, et al. "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes." New England Journal of Medicine. 2016;375(4):311-322. (LEADER trial)
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384(11):989-1002. (STEP 1 trial)
- Gadde KM, et al. "Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER)." Lancet. 2011;377(9774):1341-1352.
- Saxenda (liraglutide) injection 3 mg. U.S. Prescribing Information. Novo Nordisk. FDA label revised 2023. Available at: www.accessdata.fda.gov.
- Victoza (liraglutide) injection 1.2 mg or 1.8 mg. U.S. Prescribing Information. Novo Nordisk. Available at: www.accessdata.fda.gov.
- Flint A, et al. "Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans." Journal of Clinical Investigation. 1998;101(3):515-520. (GLP-1 central satiety mechanism)
- Knudsen LB, et al. "Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration." Journal of Medicinal Chemistry. 2000;43(9):1664-1669. (Liraglutide pharmacokinetic design including half-life data)
- United States Pharmacopeia (USP). General Chapter 1 through 1231. Injectable Preparations: Standards for Sterility, Endotoxin, and Particulates.